Larvol Delta - Ianalumab-reduces-disease-activity-across-ESSDAI-domains-Post-hoc-analysis-from-the-pooled-Phase3-NEPTUNUS1-and-NEPTUNUS2-trials-in-Sj246gren39s-disease

ianalumab (VAY736) - Novartis

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1898750&mode=presInfo

raphaele seror, MD, PhD

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next